• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetics and tissue distribution of anidulafungin in rats.阿尼芬净在大鼠体内的药代动力学及组织分布
Antimicrob Agents Chemother. 2008 Jul;52(7):2673-6. doi: 10.1128/AAC.01596-07. Epub 2008 Apr 28.
2
Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.棘白菌素类药物治疗实验性眼内白色念珠菌感染的药代动力学和药效学研究：棘白菌素类药物治疗潜在致盲性感染的应用价值。
Antimicrob Agents Chemother. 2013 Jan;57(1):281-8. doi: 10.1128/AAC.01387-12. Epub 2012 Oct 31.
3
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.阿尼芬净（LY303366）的药代动力学和药效学建模：利用最佳血浆采样对其在机会性真菌病中性粒细胞减少动物模型中的疗效进行重新评估。
Antimicrob Agents Chemother. 2001 Oct;45(10):2845-55. doi: 10.1128/AAC.45.10.2845-2855.2001.
4
Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration.连续静脉-静脉血液滤过期间阿尼芬净的多次剂量药代动力学。
J Antimicrob Chemother. 2011 Apr;66(4):880-4. doi: 10.1093/jac/dkq545. Epub 2011 Jan 22.
5
Tissue distribution of anidulafungin in neonatal rats.阿尼芬净在新生大鼠体内的组织分布。
Birth Defects Res B Dev Reprod Toxicol. 2012 Feb;95(1):89-94. doi: 10.1002/bdrb.20347. Epub 2012 Feb 6.
6
Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.阿尼芬净在腹腔内念珠菌病重症监护病房患者中的药代动力学研究。
J Antimicrob Chemother. 2017 May 1;72(5):1429-1432. doi: 10.1093/jac/dkw568.
7
Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species.新型棘白菌素CD101在多种动物物种中的药代动力学
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.01626-16. Print 2017 Apr.
8
[Role of anidulafungin in solid organ transplant recipients].阿尼芬净在实体器官移植受者中的作用
Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 14:29-34. doi: 10.1016/s0213-005x(08)76590-x.
9
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.阿尼芬净在中性粒细胞减少小鼠念珠菌病模型中的体内药效学特征
Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. doi: 10.1128/AAC.01061-07. Epub 2007 Dec 10.
10
Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance.棘白菌素类药物在疑似念珠菌性腹膜炎中的药代动力学：耐药的潜在风险。
Int J Infect Dis. 2020 Dec;101:24-28. doi: 10.1016/j.ijid.2020.09.019. Epub 2020 Sep 13.

引用本文的文献

1
Activity of rezafungin against Candida auris.瑞扎芬净对耳念珠菌的活性。
J Antimicrob Chemother. 2025 Apr 30;80(6):1482-93. doi: 10.1093/jac/dkaf124.
2
AAp-MSMD: Amino Acid Preference Mapping on Protein-Protein Interaction Surfaces Using Mixed-Solvent Molecular Dynamics.AAp-MSMD：使用混合溶剂分子动力学在蛋白质-蛋白质相互作用表面上进行氨基酸偏好映射。
J Chem Inf Model. 2023 Dec 25;63(24):7768-7777. doi: 10.1021/acs.jcim.3c01677. Epub 2023 Dec 12.
3
PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris.PK/PD 模型研究与体外实验模拟伊曲康唑联合棘白菌素类药物抗耳念珠菌活性。
CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):770-782. doi: 10.1002/psp4.12949. Epub 2023 Mar 13.
4
Cyclization and Docking Protocol for Cyclic Peptide-Protein Modeling Using HADDOCK2.4.使用 HADDOCK2.4 进行环状肽-蛋白建模的环化和对接方案
J Chem Theory Comput. 2022 Jun 14;18(6):4027-4040. doi: 10.1021/acs.jctc.2c00075. Epub 2022 Jun 2.
5
Human Tissue Distribution of Anidulafungin and Micafungin.阿尼芬净和米卡芬净的人体组织分布。
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0016921. doi: 10.1128/AAC.00169-21.
6
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.基于已建立的人体药代动力学得出的血浆和靶部位浓度，对抗 SARS-CoV-2 药物再利用机会进行优先排序。
Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909. Epub 2020 Jun 14.
7
Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.儿科患者全身用抗真菌药物的给药途径和剂量。
Paediatr Drugs. 2020 Apr;22(2):165-188. doi: 10.1007/s40272-020-00379-2.
8
Antifungal Drugs: Special Problems Treating Central Nervous System Infections.抗真菌药物：治疗中枢神经系统感染的特殊问题
J Fungi (Basel). 2019 Oct 11;5(4):97. doi: 10.3390/jof5040097.
9
Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagy.寿命延长药物去甲二氢愈创木酸抑制p300并激活自噬。
NPJ Aging Mech Dis. 2019 Oct 2;5:7. doi: 10.1038/s41514-019-0037-7. eCollection 2019.
10
SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [C]SCY-078 in Albino and Pigmented Rats.在静脉内和口服 [C]SCY-078 于白化和色素沉着大鼠的体内物质平衡研究中，新型杀真菌剂 SCY-078 显示向与真菌感染相关的组织分布。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.02119-18. Print 2019 Feb.

本文引用的文献

1
Anidulafungin versus fluconazole for invasive candidiasis.阿尼芬净与氟康唑治疗侵袭性念珠菌病的比较
N Engl J Med. 2007 Jun 14;356(24):2472-82. doi: 10.1056/NEJMoa066906.
2
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.对于持续性中性粒细胞减少的小鼠，每周一次的米卡芬净治疗在播散性念珠菌病的治疗效果上与每日治疗相当。
Antimicrob Agents Chemother. 2007 Mar;51(3):968-74. doi: 10.1128/AAC.01337-06. Epub 2006 Dec 28.
3
The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.棘白菌素类药物：其药代动力学、药效学及临床应用的比较
Pharmacology. 2006;78(4):161-77. doi: 10.1159/000096348. Epub 2006 Oct 17.
4
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.阿尼芬净在患有播散性念珠菌病的中性粒细胞减少小鼠中的药代动力学及微生物反应
Antimicrob Agents Chemother. 2006 Nov;50(11):3695-700. doi: 10.1128/AAC.00507-06. Epub 2006 Sep 5.
5
Anidulafungin: a novel echinocandin.阿尼芬净：一种新型棘白菌素。
Clin Infect Dis. 2006 Jul 15;43(2):215-22. doi: 10.1086/505204. Epub 2006 Jun 9.
6
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.卡泊芬净在系统性念珠菌病小鼠模型中的药效学：卡泊芬净在组织中持续存在对理解药物活性的重要性。
Antimicrob Agents Chemother. 2005 Dec;49(12):5058-68. doi: 10.1128/AAC.49.12.5058-5068.2005.
7
Pharmacokinetics/pharmacodynamics of echinocandins.棘白菌素类的药代动力学/药效学
Eur J Clin Microbiol Infect Dis. 2004 Nov;23(11):805-12. doi: 10.1007/s10096-004-1228-z. Epub 2004 Oct 14.
8
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.阿尼芬净与氟康唑治疗食管念珠菌病的随机双盲试验。
Clin Infect Dis. 2004 Sep 15;39(6):770-5. doi: 10.1086/423378. Epub 2004 Aug 27.
9
Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats.给大鼠静脉注射抗真菌药物米卡芬净后的组织分布。
Biol Pharm Bull. 2004 Jul;27(7):1154-6. doi: 10.1248/bpb.27.1154.
10
Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.新型抗真菌药物卡泊芬净在小鼠、大鼠、兔和猴体内的处置情况。
Antimicrob Agents Chemother. 2004 Apr;48(4):1272-80. doi: 10.1128/AAC.48.4.1272-1280.2004.

阿尼芬净在大鼠体内的药代动力学及组织分布

Pharmacokinetics and tissue distribution of anidulafungin in rats.

作者信息

Damle Bharat, Stogniew Martin, Dowell James

机构信息

Pfizer Inc., New York, New York 10017, USA.

出版信息

Antimicrob Agents Chemother. 2008 Jul;52(7):2673-6. doi: 10.1128/AAC.01596-07. Epub 2008 Apr 28.

DOI:10.1128/AAC.01596-07
PMID:18443124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2443878/
Abstract

This study assessed the tissue distribution of anidulafungin in rats. Anidulafungin rapidly distributed into tissues, achieving peak concentrations within 30 min, and maintained levels above MICs for common pathogens over 72 h. In tissues susceptible to fungal infection (liver, lung, spleen, kidney), exposure was 9- to 12-fold higher than in plasma.

摘要

本研究评估了阿尼芬净在大鼠体内的组织分布情况。阿尼芬净迅速分布至各组织，在30分钟内达到峰值浓度，并在72小时内维持高于常见病原体最低抑菌浓度的水平。在易受真菌感染的组织（肝脏、肺、脾脏、肾脏）中，药物暴露量比血浆中高9至12倍。